Advanced International Breast Cancer Course (AIBCC)

Aims

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. For these reasons, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the “classic” clinical specialties. Finally, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.

With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 14^th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 14^th AIBCC will award the 8^th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. For the first time, we also welcome the presentation of posters from the participants and the bets poster will be awarded during the Award Cerimony.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

Addressed to

Physicians specialized in anatomical pathology, gynaecology and obstetrics, oncology, radiology, radiotherapy. Biologists, pharmacists and nurses.

It won’t be possible give credits to physicians specialized in different fields.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

University of Padua award for advances in breast cancer 2018

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

Fellowships

Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within July 1^st.
The organizing secretariat will confirm the award of the fellowship within July 20^th and it will proceed with the organization of logistics.

Free admission is available for 3 persons “under 35”. Registration forms will be accepted on a first-come, first-served basis unitil spaces are filled. The Organization Secretariat will confirm the registration by email.

CME

Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31)  will assign to the activity CME (31-228175): 11,2 CME points.

The credit certification is subject to:

• Professions/specializations should correspond to those which have been accredited for CME;
• 90% attendance to the meeting;
• Completion of the meeting evaluation form;
• Completion of the final questionnarie (at least 75% of correct answers).

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

Participants can send one or more abstracts.

The form should be filled out by following specific guidelines:

• Use the capitol letter for the title
• Indicate each author's affiliation (that should include institution, department and town)
• Underline the designated presenting author’s name.
• Use font Times New Roman 10, single line spacing.

Abstracts will be selected by the Scientific Committee and will be shown during the poster session on September 22^nd from 8 am. Poster size: 90 cm wide and 120 cm high (portrait).

People sending the selected abstracts will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement € 200,00 for Italian participants and € 300,00 for European participants).

Abstracts should be sent within July 15^th. A confirmation will be sent by email within July 20^th.

Download Form

Send abstract

Sorry, too late! Dead line was 07/15 2018!

Thursday, September 20^th

8.30

Registration

9.15

Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi

 

SESSION I - EVOLUTION IN BREAST CANCER PREVENTION

Chairmen: Francesca Caumo, Stefania Zovato

9.30

Population screening vs risk-adapted surveillance
Sylvia Heywang – Kobrunner

9.50

Pharmacological prevention: how and whom?
Elefterios Mamounas

10.10

A look into the future: multigene panels
Gabriel N. Hortobagyi

10.30

Q&A

10.45

Coffee break

 

SESSION II - LOCOREGIONAL TREATMENT

Chairmen: Jacek Jassem, Gabriel N. Hortobagyi

11.15

Evolution in surgical management of the axilla
Viviana E. Galimberti

11.45

Do margins still matter for in situ and invasive lesions?
Elefterios Mamounas

12.15

Radiation therapy: what is the real target to aim at
Philip Poortmans

12.45

Q&A

13.00

Lunch

14.00

Multidisciplinary Tumor Board 1 – Locoregional treatment

• Case 1: Locoregional relapse (questions: locoregional treatment with or without radiosensitisers (drugs; hyperthermia; EF)? “adjuvant” systemic treatment?) – Laura Martella
• Case 2: Breast cancer in a patient previously treated with RT for Hodgkin disease (questions: locoregional treatment? contralateral mastectomy?) – Tania Saibene
• Case 3: Healthy patient with familial history asking for risk-reducing mastectomy – Silvia Michieletto
• Concluding comments – Jacek Jassem

 

SESSION III – SUPPORTIVE AND COMPLEMENTARY THERAPIES

Chairmen: Pier Franco Conte, Stefania Migliuolo

15.00

Diet: myths and facts
Mariateresa Nardi

15.20

Complementary therapies
Claudia Bozza

15.40

Scalp cooling
Laura Marchioro

16.00

Q&A

10.20

Coffee break

 

SESSION IV – LONG TERM CONSEQUENCES OF SYSTEMIC TREATMENTS

Chairmen: Hesham Ahmed Gaballah Elghazaly, Valentina Guarneri

16.40

Gynecologic
Marco Gambacciani

17.00

Cardiovascular and metabolic
Thomas Suter

17.20

Bone health
Ingo Diel

17.40

Q&A

18.00

Adjourn

Friday, September 21^st

 

SESSION V – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY

Chairmen: Enrico Orvieto, Peter Schmid

9.00

HER2 testing guidelines: new ASCO/CAP 2018
Giuseppe Viale

9.20

Molecular stratification of HER2+ and TNBC
Aleix Prat

9.40

Lobular breast cancer: a separate entity?
Caterina Marchiò

10.00

Q&A

10.20

Coffee Break

 

SESSION VI – NEW PATHWAYS AND NEW DRUGS

Chairmen: Sybille Loibl, Aleix Prat

10.50

Insights in resistance to CDK4/6 inhibitors
Stephen Johnston

11.10

Targeting the immune system: hopes and hypes
Peter Schmid

11.30

Combining radiotherapy and immunotherapy
Emanuela Romano

11.50

PARPi and other promising agents
Gabriel N. Hortobagyi

12.10

Q&A

12.30

Lunch

 

SESSION VII – SYSTEMIC TREATMENTS FOR EARLY BREAST CANCER

Chairmen: Stephen Johnston, Gabriel N. Hortobagyi

14.00

Extended adjuvant endocrine therapy: why? for whom? with what?
Michael Gnant

14.30

Risk adapted adjuvant treatment for HER2+ disease
Pier Franco Conte

15.00

Most promising ongoing trials in early disease
Hope Rugo

15.30

Q&A

16.00

Multidisciplinary Tumor Board 2 – Early Breast Cancer: challenging cases for pathologists and clinicians

• Case 1: Rare histologies (pleomorphic lobular carcinoma, low aggressive triple negative histologies, micropapillary eyc) – Vassilena Tsvetkova
• Case 2: HER2+ (de-escalated treatments for HER2+ disease) – Giulia Tasca
• Case 3: Management of non pCR after neoadjuvant chemotherapy – Carlo Alberto Giorgi
• Concluding comments – Maria Vittoria Dieci

17.00

Adjourn

17.30

Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2018 and best poster award

17.45

Lecture of the Awardee

18.15

Cocktail

19.30

Adjourn

Saturday, September 22^nd

 

SESSION VIII – Advanced Breast Cancer

Chairman: Pier Franco Conte, Stephen Johnston

9.00

New therapeutic algorithms
HR+ disease - Sibylle Loibl
HER2+ disease - Valentina Guarneri
TN disease - Miguel Martin

10.30

Q&A

10.40

Coffee break

11.00

Do elderly patients require special management?
Matti Aapro

11.20

Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer
Chairman: Sandra Swain
Panelists: Giulia Valeria Bianchi, Jacek Jassem, Philip Poortmans, Hope Rugo

• Case 1: Bone disease – Zora Baretta
• Case 2: Brain mets – Gaia Griguolo
• Case 3: Fulminat visceral disease – Luisa Carbognin
• Case 4: Oligometastatic disease – Giacomo Pelizzari
• Concluding comments – Sandra Swain

12.45

Adjourn and final evaluation questionnaire

Registration Fee

€ 250,00

€ 150,00 For graduate students and nurses

Tax free.

They include the conference bag and all coffee breaks and lunches. They do not include Hotel accomodation, dinners and travel expenses.